Innovent Biologics, Inc.: Neoplasms trials

The registry lists 27 Neoplasms studies with Innovent Biologics, Inc. as lead sponsor. 4 are open to participants now and 2 have results posted.

Phase 1 27Phase 2 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of IBI3005 in Subjects with Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT06418061Phase 1
• A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT05923008Phase 1/2
• A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05636215Phase 1/2
• Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced MalignanciesRecruitingNCT05164458Phase 1
• IBI308 in Subjects With Advanced/Metastatic Solid MalignanciesCompletedNCT03568539Phase 1Results posted
• First in Human Study of IBI308 in Chinese Subjects With Advanced Solid TumorsCompletedNCT02937116Phase 1Results posted
• IBI397 or Combination Therapies in Patients With Advanced MalignanciesWithdrawnNCT05245916Phase 1
• A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid TumorsStatus unknownNCT05172856Phase 1
• A Phase I Study of IBI325 in Patients With Advanced Solid TumorCompletedNCT05119998Phase 1
• Study of IBI323 in Patients With Advanced MalignanciesStatus unknownNCT04916119Phase 1
• IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.CompletedNCT04912466Phase 1
• A Study of Dose Escalation of IBI321 in Patients With Advanced Solid TumorsCompletedNCT04911894Phase 1
• A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid TumorsCompletedNCT04911881Phase 1
• A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic MalignancyCompletedNCT04795128Phase 1
• Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant TumorsStatus unknownNCT04708210Phase 1
• A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsCompletedNCT04353830Phase 1
• A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced CancersCompletedNCT04338659Phase 1
• Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant TumorsCompletedNCT04328831Phase 1
• Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR AlterationsCompletedNCT04258527Phase 1
• A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid TumorCompletedNCT04162327Phase 1
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant TumorsStatus unknownNCT04085185Phase 1
• Study of IBI318 in Participants With Advanced MalignanciesCompletedNCT03875157Phase 1
• A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and LymphomasCompletedNCT03763149Phase 1
• First in Human Study of IBI101 in Chinese Subjects With Advanced Solid TumorsCompletedNCT03758001Phase 1
• A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced MalignanciesCompletedNCT03717103Phase 1
• A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.CompletedNCT03545971Phase 1